^Flekhter, Oxana B. (2000). "Nooglutil, Russian Academy of Medical Science". Current Opinion in Central & Peripheral Nervous System Investigational Drugs. 2 (4): 491–497.
^V. V. Yasnetsov; V. A. Pravdivtsev; V. M. Popov; T. A. Voronina; N. M. Kiseleva; S. B. Kozlov (May 1995). "Antimotion Effect of Nooglutyl and Its Neuronal Mechanism". Bulletin of Experimental Biology and Medicine. 119 (5): 515–516. doi:10.1007/BF02543440. PMID7579248. S2CID6344628.
^Voronina, TA; Borlikova, GG; Garibova, TL; Proskuryakova, TV; Petrichenko, OB; Burd, SG; Avakyan, GN (2002). "Effect of nooglutil on benzodiazepine withdrawal syndrome and binding of 3H-spiperone with D2 receptors in rat striatum". Bulletin of Experimental Biology and Medicine. 134 (5): 448–50. doi:10.1023/a:1022634112815. PMID12802448. S2CID142803.
^Garibova, TL; Galaeva, IP; Voronina, TA; Kraĭneva, VA; Kapitsa, IG; Kirichenko, SV; Makarenko, AN; Mirzoian, GR; Kuznetsova, EA (2003). "Effect of nooglutil on rats with intracerebral posttraumatic hematoma (hemorrhagic stroke)". Eksperimental'naia i Klinicheskaia Farmakologiia. 66 (3): 13–6. PMID12924225.
^Povarova, OV; Garibova, TL; Kalenikova, EI; Galaeva, IP; Kraĭneva, VA; Medvedev, OS; Voronina, TA (2004). "Effect of phenyl-tert-butylnitrone, mexidol and nooglutil on the ischemic lesion zone and memory in rats following middle cerebral artery occlusion". Eksperimental'naia i Klinicheskaia Farmakologiia. 67 (1): 3–6. PMID15079898.